Gene Therapy (2011) 18, 1180

www.nature.com/gt

CORRIGENDUM

Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle

H Karvinen, E Pasanen, TT Rissanen, P Korpisalo, E Vähäkangas, A Jazwa, M Giacca and S Ylä-Herttuala

Gene Therapy (2011) **18,** 1180; doi:10.1038/gt.2011.93; published online 9 June 2011

Correction to: *Gene Therapy* advance online publication, 12 May 2011; doi:10.1038/gt.2011.66

Since the online publication of this paper the authors have noticed that Figure 2 is incorrect. The Doppler data are missing in panels i and j. The correct figure is shown below.

The authors would like to apologise for this error.



Figure 2 Muscle perfusion imaged by contrast pulse sequence (CPS) ultrasound technique in normal muscles (**a–d**) and after ischemia operation (**e–h**). Native image after AAV-VEGF-A-A_{165} injection, asterisk indicates the location of the injection (**a**). CPS images from the same muscle 1 month (**b**) and 12 months (**d**) after AAV-VEGF-A-A_{165} gene transfer. Power Doppler image after AAV-VEGF-A-A_{165} gene transfer (**c**). Power Doppler (**e**) and CPS (**f**) images 6 months after ischemia operation and AAV-LacZ gene transfer. Power Doppler (**g**) and CPS (**h**) images 6 months after ischemia operation and AAV-VEGF-A-A_{165} gene transfer. Arrowheads in Doppler images indicate the signal from large vessels. Perfusion ratio to contralateral intact in normal muscles (**i**) and in ischemic muscles (**j**). Perfusion in VEGF-A-transduced muscle was increased compared with LacZ muscle already 1 week after gene transfer both in normoxic and in ischemic muscles. Results are presented as means ± s.e.m., $^*P \leqslant 0.05$, $n=3$.